SAPPHIRE

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, BMP6, SAPPHIRE, Anemia, American College, Society, DRAGON, Extracellular matrix, Gongshi, Immunotherapy, Neurology, Completeness, Conference, Degenerative disease, Patient, SMA, Toxicology, Research, Fibrosis, Clinical trial, Rock, Pharmaceutical industry, Vaccine

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.
  • The last patient is expected to be enrolled in SAPPHIRE in 2023, with the top-line data readout expected in 2024.
  • Scholar Rock is expecting to provide biomarker and clinical updates from the DRAGON Phase 1 trial in 2023.
  • Scholar Rock plans to advance a highly selective, RGMc/HJV antibody that targets the signaling of BMP6, a key regulator of iron availability in the body.

Velo3D to Transform its Production Operations With the Hiring of Brad Kreger as Executive Vice President of Operations

Retrieved on: 
Tuesday, December 13, 2022
Other Manufacturing, Technology, Public Relations, Investor Relations, Chemicals, Plastics, Communications, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, Consumer Electronics, Fluidigm, Bay, Honeywell, VELO, Flow, XC, Affymetrix, Lam Research, SpaceX, Thermo Fisher Scientific, Global Operations, Battlecross, Quality assurance, NYSE, San Francisco, AM, All rights reserved, VLD, Multimedia, Growth, Senior, Aviation, SAPPHIRE, Defence Intelligence Fusion Centre, Forecasting, FLOW, Management, 3D printing, Risk management, Sapphire, Operation

Kreger brings decades of experience overseeing and rapidly scaling operations in hardware production, including tenures at Thermo Fisher Scientific and its subsidiary Affymetrix, and Fluidigm Corporation.

Key Points: 
  • Kreger brings decades of experience overseeing and rapidly scaling operations in hardware production, including tenures at Thermo Fisher Scientific and its subsidiary Affymetrix, and Fluidigm Corporation.
  • View the full release here: https://www.businesswire.com/news/home/20221213005067/en/
    Brad Kreger, Executive Vice President of Operations at Velo3D (Graphic: Business Wire)
    Kregers career has centered around early-stage companies that are scaling the manufacturing of hardware while also making improvements in quality and cost.
  • I look forward to seeing Brad optimize our operations to accelerate the production our Sapphire and Sapphire XC printers, increase our manufacturing capabilities, and reach our production goals for 2023 and beyond.
  • In his new role overseeing production, Kreger will lead all operations activities at Velo3D, including global logistics, manufacturing, quality, and procurement.

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Retrieved on: 
Friday, December 2, 2022
KIT, NSCLC, Receptor tyrosine kinase, VEGFR2, SAPPHIRE, Judgement, TAM, Mer, Large-cell lung carcinoma, Therapy, Cancer, Research, Life, PRMT5, Patient, TYRO3, Science, Lung cancer, SAN, Nivolumab, Pharmaceutical industry, Mirati

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023.

Key Points: 
  • "We remain committed to developing our portfolio of oncology candidates and advancing our lung cancer strategy to positively impact the lives of patients with cancer.
  • Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12Dinhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
  • For more information about Mirati Therapeutics, Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Industrial Alcohol Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, November 25, 2022
Starch, BASF, Carbon, Fermentation, Solvent, Adhesive, Sigma-Aldrich, Univar Solutions, Green Plains Inc., The Andersons, Detergent, Shell Canada, Koch Industries, Liniment, Biofuel, POET, Acquisition, Molasses, Benzyl alcohol, Microbial contamination of diesel fuel, Gasoline, SAPPHIRE, Poet, Ethanol, Growth, Corn oil, COVID-19, Organization, Air pollution, Cosmetics, Doe-Anderson Inc., MGP, ExxonMobil, Beer, Renewable energy, E10

The industrial alcohol market consists of sales of industrial alcohol by entities (organizations, sole traders, and partnerships) that are used in the production of vaccinations, compound tonics, syrups, tinctures, liniments, and antiseptics.Industrial alcohol is a kind of alcohol that is utilized in industrial applications.

Key Points: 
  • The industrial alcohol market consists of sales of industrial alcohol by entities (organizations, sole traders, and partnerships) that are used in the production of vaccinations, compound tonics, syrups, tinctures, liniments, and antiseptics.Industrial alcohol is a kind of alcohol that is utilized in industrial applications.
  • The main types of industrial alcohol include isopropyl alcohol, methyl alcohol, ethyl alcohol, isobutyl alcohol, and benzyl alcohol.Isopropyl alcohol is used as an ingredient in various cosmetics and medicinal preparations for external use.
  • The regions covered in the industrial alcohol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The industrial alcohol market research report is one of a series of new reports that provides industrial alcohol market statistics, including industrial alcohol industry global market size, regional shares, competitors with an industrial alcohol market share, detailed industrial alcohol market segments, market trends and opportunities, and any further data you may need to thrive in the industrial alcohol industry.

Vertex Manufacturing Orders Two Additional Sapphire XC 3D Printers, Including the First Large-format GRCop-42 System in Velo3D’s Contract Manufacturer Network

Retrieved on: 
Tuesday, November 15, 2022
Software, Professional Services, Hardware, Technology, Automotive, Other Manufacturing, Engineering, Chemicals, Plastics, Automotive Manufacturing, Other Technology, Manufacturing, Other Science, Defence Intelligence Fusion Centre, CNC, GE Aviation, NASA, Quality assurance, VLD, Lam Research, Chromium, VELO, Partnership, Copper, FLOW, NYSE, SpaceX, Morris, Honeywell, Flow, Aviation, All rights reserved, San Francisco, FANUC, AM, MTI, Inconel, Business development, Bay, SAPPHIRE, 3D printing, Risk management, Vertex, Sapphire

As a leader in additive manufacturing (AM) and secondary processes, Vertex specializes in providing effective solutions to demanding customer engineering challenges.

Key Points: 
  • As a leader in additive manufacturing (AM) and secondary processes, Vertex specializes in providing effective solutions to demanding customer engineering challenges.
  • Available at scale, Vertex also offers manufacturing using GRCop-42, a copper, chromium and niobium alloy that was developed by NASA for use in regeneratively-cooled rocket engines.
  • With these technologies, customers spanning multiple critical industries including aerospace, space, medical devices, and semiconductor, can rely on Vertex for all challenging scenarios.
  • As the AM landscape continues to mature, the technology has become invaluable, enabling faster product development times and significantly reduced manufacturing cycles, stated Tim Warden, VP of Sales and Manufacturing at Vertex Manufacturing.

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Medicare Part D, Clinical trial, Cancer, Security (finance), Growth, Society for Immunotherapy of Cancer, Spectrochimica Acta Part B, Immunotherapy, Silicon Valley Bank, R, Medical Affairs Bureau, FAQ, Social media, SMA, Research, DRAGON, Society, CMO, RECIST, Intellectual property, Executive, COVID-19, Rock, Silicon, SAPPHIRE, Ageing, Merck, File, Annual general meeting, Spinal muscular atrophy, Drug Quality and Security Act, Human, Gongshi, Acceleron Pharma, Neurology, WMS, Fibrosis, Risk, Neuromuscular Disorders, Degenerative disease, Net, Head, SITC, Patient, Pharmaceutical industry, Palladium, Part

I am excited to strengthen our experienced executive team with the addition of Scholar Rocks new CMO, Dr. Jing Marantz.

Key Points: 
  • I am excited to strengthen our experienced executive team with the addition of Scholar Rocks new CMO, Dr. Jing Marantz.
  • Revenue was $0 for the quarter ended September 30, 2022, compared to $5.5 million for the quarter ended September 30, 2021.
  • General and administrative expense was $10.5 million for the quarter ended September 30, 2022, compared to $11.3 million for the quarter ended September 30, 2021.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

Retrieved on: 
Wednesday, November 9, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Neuromuscular Disorders, Research, Hematology, FAQ, Therapy, Berkeley, Molecular biology, Medical University of South Carolina, Company, Human, Medical school, Security (finance), Securities Act of 1933, Arcturus, Industry, Acceleron Pharma, Review, Tongji Medical College, Multimedia, U.S. Securities and Exchange Commission, DRAGON, Takeda Oncology, Global Affairs Canada, Cancer, Patient, Social media, SAPPHIRE, Gongshi, ARCT, COVID-19, Investor, Private Securities Litigation Reform Act, Fibrosis, Medical Affairs Bureau, Risk, Nephrology, Alnylam Pharmaceuticals, R, Clinical trial, Degenerative disease, Growth, Executive, Arcturus Therapeutics, SMA, Intellectual property, Rock, File, Doctor of Philosophy, Biogen, NASDAQ, Safety, University, Neurology, Public relations, Pharmaceutical industry, Biochemistry, Alexion

View the full release here: https://www.businesswire.com/news/home/20221109005240/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221109005240/en/
    We are thrilled to welcome Jing to Scholar Rock as Chief Medical Officer.
  • Her broad and deep expertise in leading development and medical affairs will be instrumental in helping us advance our clinical programs and differentiated platform in targeting the TGF superfamily, said Jay Backstrom, M.D., M.P.H., Chief Executive Officer of Scholar Rock.
  • Most recently, Dr. Marantz served as the Executive Vice President and Chief Business Officer at Krystal Biotech.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, November 8, 2022
Food, Pembrolizumab, IND, NASDAQ, NDA, Oncology, Lung cancer, Judgement, U.S. Securities and Exchange Commission, Meekness, Growth, FDA, Patient, SEC, TAM, Company, Fast Track, CRC, SAN, European Society for Medical Oncology, Cancer, NSCLC, ESMO, Trial of the century, Life, Program, MTAP, Prescription Drug User Fee Act, CMO, Cetuximab, Retirement, PDUFA, SOS1, Neoplasm, Investment, Nivolumab, Science, Leadership, Food and Drug Administration Amendments Act of 2007, Investigational New Drug, Incyte, SAPPHIRE, Research, PRMT5, Therapy, MTA, Congress, Pharmaceutical industry, Management, Medical device, Aquaculture, Facebook, BeiGene, Mirati

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.
  • We continue to advance our pipeline and capabilities, further enabling Mirati to transform the lives of people living with cancer."
  • ET / 1:30 p.m. PT during which company executives will review financial information for the third quarter of 2022 and provide corporate updates.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

AVANGRID’s Digital Summit Showcases Latest in Disruptive Technology

Retrieved on: 
Monday, October 31, 2022
Environment, Technology, Other Energy, Utilities, Oil, Gas, Sustainability, Alternative Energy, Green Technology, Networks, Energy, Growth, Climate change, Organization, IBM, Industry, NTT, Schneider Electric, Environment, Ethisphere Institute, Innovation, JUST, Avangrid, NYSE, Technology, Learning, Artificial intelligence, ESRI, IOT, Alumil Aluminium Industry S.A., Culture, Accenture, SAP, Workforce, Deloitte, Wind, Iberdrola, ESG, Robotics, Copenhagen Infrastructure Partners, GW, Public utility, Internet of things, SAPPHIRE, Microsoft, AGR, Wipro, Network, NTT DATA, AWS, Machine learning, Carbon, United Kingdom, Goal, Utility, Video game, Renewable energy

A diverse array of technology leaders converged at the Connecticut headquarters of AVANGRID (NYSE: AGR) last week to showcase the latest in digital solutions for the energy sector as part of AVANGRIDs second annual Digital Summit.

Key Points: 
  • A diverse array of technology leaders converged at the Connecticut headquarters of AVANGRID (NYSE: AGR) last week to showcase the latest in digital solutions for the energy sector as part of AVANGRIDs second annual Digital Summit.
  • AVANGRIDs 2022 Digital Summit demonstrates our commitment to digital transformation and creates a powerful learning and collaborative environment to ensure we keep evolving.
  • Its two-day event was part of Iberdrolas global Digital Summit series, which includes similar events for its companies in Brazil, Mexico and the U.K.
  • AVANGRIDs Digital Summit and ITechShows have been a showcase of a great culture of innovation.

Velo3D Appoints Jessie Lockhart as Chief People Officer

Retrieved on: 
Thursday, October 20, 2022
Other Manufacturing, Technology, Engineering, Chemicals, Plastics, Other Technology, Automotive Manufacturing, Aerospace, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, People, Adoption, LinkedIn, Education, Bay, Master of Business Administration, Culture, SEC, Growth, Business administration, AM, All rights reserved, Employment, NYSE, Psychology, FLOW, Novellus Systems, Twitter, Workforce, Multimedia, Defence Intelligence Fusion Centre, Technology, Private Securities Litigation Reform Act, Pepperdine University, CPP, Company, Acquisition, San Francisco, SpaceX, Flow, CEO, Lam Research, Optimism, Leadership, Bachelor, Quality assurance, Honeywell, Aviation, Solution, SAPPHIRE, View, San Jose State University, VELO, VLD, Management, 3D printing, Risk management, Sapphire

Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Jessie Lockhart as Chief People Officer.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Jessie Lockhart as Chief People Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221020005413/en/
    Jessie Lockhart, Chief People Officer at Velo3D (Photo: Business Wire)
    Velo3D has experienced extensive growth in its workforce over the past year since becoming a publicly listed company, including rapid expansion in Europe and Asia-Pacific.
  • Jessie brings with her an amazing background of working with high-growth, innovative companies that have successfully undergone periods of rapid expansion.
  • VELO, VELO3D, SAPPHIRE, and INTELLIGENT FUSION, are registered trademarks of Velo3D, Inc.; and WITHOUT COMPROMISE, FLOW and ASSURE are trademarks of Velo3D, Inc. All Rights Reserved Velo3D, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005413/en/